Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Understand the compelling reasons to get a no annual fee travel card. Enjoy perks without the extra charges.
26,540 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
A renewable-powered data-center company, Iren, surged after unveiling a multi-year Nvidia partnership and ambitious A...
Could eBay join the meme stock conversation? This article breaks down what it means for investors, the driver behind ...
As Bitcoin hovers in the mid-$30,000s in June 2026, investors ask whether will bitcoin make millionaire? fortunes pos...
HIVE Digital Tech shares surged as analysts raised targets ahead of earnings, highlighting AI data centers' growing r...
When a major investor's affiliate sells a stake in Coursera, it prompts questions about future growth and risk. This ...
Ford investors are watching for signs of real momentum beyond headlines. This article breaks down the latest little g...
IBM's latest profit warning sheds light on the strength and limits of AI demand, cloud growth, and enterprise spendin...
As investors eye fastenal (FAST) 2026 earnings, the focus is on demand cycles, margin resilience, and cash flow stren...
Tilray Brands is expanding beyond its cannabis roots into beverages and other segments. This article examines whether...
Great Elm's Q3 2026 earnings shed light on growth, margins, and capital allocation. This article breaks down the numb...
A hantavirus outbreak can spark biotech chatter, but three solid realities—limited demand, tough development paths, a...